TNF and inflammatory bowel disease: A multicenter cohort study by Amiot et al[38] evaluated the efficacy of vedolizumab in IBD patients with prior TNF antagonist failure, resulting in clinical remission rates of 36% and 39% in the CD and UC groups, respectively, after 14 weeks of induction therapy.